<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043298</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI360A101</org_study_id>
    <nct_id>NCT05043298</nct_id>
  </id_info>
  <brief_title>A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase Ia/Ib Open-Label, Multi-Center Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label Phase Ia trial to evaluate safety, tolerability, pharmacokinetics and&#xD;
      preliminary efficacy of IBI360 monotherapy in Advanced or Metastatic Solid Tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase Ia is dose escalation and dose expansion study of IBI360 monotherapy in advanced or&#xD;
      metastatic Solid Tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 7, 2021</start_date>
  <completion_date type="Anticipated">June 18, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 25, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerance</measure>
    <time_frame>up to 90 days following last dose</time_frame>
    <description>Participant safety is characterized by frequency and severity of adverse events(according to NCI CTCAE 5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>up to 21 days following last dose level</time_frame>
    <description>A recommended phase 2 dose will be determined based on safety data including dose limiting toxicities, preliminary efficacy data, and PK data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>Subjects were randomized 6 months and 1 year later</time_frame>
    <description>Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration vs time curve(AUC)</measure>
    <time_frame>Up to 48 weeks following first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration(Cmax)</measure>
    <time_frame>Up to 48 weeks following first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half Life（T1/2）</measure>
    <time_frame>Up to 48 weeks following first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>up to 90 days following last dose</time_frame>
    <description>Incidence of anti-drug antibodies (ADA) will be measured</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>IBI360</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI 360 Injection</intervention_name>
    <description>IBI 360 dose level of escalation IV Q3W Day 1</description>
    <arm_group_label>IBI360</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide signed informed consent;&#xD;
&#xD;
          2. Male or female aged at 18-75 (inclusive) years;&#xD;
&#xD;
          3. Expected survival ≥12 weeks;&#xD;
&#xD;
          4. ECOG PS score 0 or 1;&#xD;
&#xD;
          5. Provide archival or fresh tissues for CLDN18.2 expression analysis;&#xD;
&#xD;
          6. Adequate laboratory parameters;&#xD;
&#xD;
          7. Suffer from advanced or metastatic malignant local solid tumors confirmed by&#xD;
             histological diagnosis and meet the criteria of the enrolled group as follows:&#xD;
&#xD;
        Ia: The subjects for whom no standard treatment regimens are available or who is&#xD;
        intolerable to standard treatments.&#xD;
&#xD;
        Ib: pancreatic carcinoma, HER2 negative gastric adenocarcinoma, advanced or metastatic&#xD;
        solid tumors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subjects who received the treatment with CLDN18.2 monoclonal antibody or CLDN-18.2&#xD;
             CART;&#xD;
&#xD;
          2. The subjects who received other anti-tumor medication within 4 weeks prior to the&#xD;
             initial dose of the study drug;&#xD;
&#xD;
          3. Any toxicity due to previous anti-tumor therapy that has not yet resolved to NCI CTCAE&#xD;
             v5.0 grade 0 or 1 prior to the first dose of study treatment;&#xD;
&#xD;
          4. The subjects with history of hypersensitivity to the study drug;&#xD;
&#xD;
          5. The subjects were not recovery after surgery with history of gastrointestinal&#xD;
             perforation or fistula within 6 months prior to the enrollment;&#xD;
&#xD;
          6. The subjects with symptomatic central nervous system (CNS) metastasis or carcinomatous&#xD;
             meningitis;&#xD;
&#xD;
          7. The subjects with pyloric obstruction;&#xD;
&#xD;
          8. The subjects with active or poorly controlled serious infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>feng ye</last_name>
    <phone>05922137572</phone>
    <email>yefengdoctor@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Innovent Biologics (suzhou) Co. , Ltd.</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>yunxia feng</last_name>
      <phone>13553093695</phone>
      <email>yunxia.feng@innoventbio.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 5, 2021</study_first_submitted>
  <study_first_submitted_qc>September 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 5, 2021</last_update_submitted>
  <last_update_submitted_qc>September 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

